Russia. Developments in the Computation of the Maximum Supply Price for Medicinal Drugs Included in the List

The new methodology establishes the procedure for the determination of the maximum supply price for vital and essential drugs by manufacturers which carry out primary and (or) secondary packaging operations in the Russian Federation and by manufacturers of member states of the Eurasian Economic Union.

It is proposed that, in the case of generic drugs, the maximum supply price should not be permitted to exceed 80% of the registered maximum supply price for a “reference drug”, or, if the latter does not exist, should not be permitted to exceed 80% of the maximum registered price for a “similar” drug.

In the case of biosimilar drugs, the maximum supply price would not be permitted to exceed 90% of the registered maximum supply price for a “reference drug”, or, if the latter does not exist, would not be permitted to exceed 90% of the maximum registered price for a “similar” drug.

Source: EY Russia